CS
TBPH icon

Credit Suisse’s Theravance Biopharma TBPH Stock Holding History

Credit Suisse’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.04M Hold
115,418
– – ﹤0.01% 2244
2023
Q4 		$1.3M Buy
115,418
+30,733
+36% +$309K ﹤0.01% 2166
2023
Q3 		$731K Sell
84,685
-2,703
-3% -$26.1K ﹤0.01% 2479
2023
Q2 		$904K Sell
87,388
-72,555
-45% -$801K ﹤0.01% 2447
2023
Q1 		$1.74M Buy
159,943
+59,718
+60% +$631K ﹤0.01% 1966
2022
Q4 		$1.12M Buy
100,225
+28,605
+40% +$301K ﹤0.01% 2260
2022
Q3 		$727K Buy
71,620
+382
+0.5% +$3.58K ﹤0.01% 2558
2022
Q2 		$646K Buy
71,238
+5,890
+9% +$54.3K ﹤0.01% 2683
2022
Q1 		$624K Sell
65,348
-913
-1% -$8.95K ﹤0.01% 2843
2021
Q4 		$732K Sell
66,261
-3,392
-5% -$29.6K ﹤0.01% 3554
2021
Q3 		$516K Buy
69,653
+6,931
+11% +$77.5K ﹤0.01% 3779
2021
Q2 		$910K Buy
62,722
+13,888
+28% +$261K ﹤0.01% 3465
2021
Q1 		$996K Sell
48,834
-13,685
-22% -$260K ﹤0.01% 3327
2020
Q4 		$1.11M Buy
62,519
+17,534
+39% +$315K ﹤0.01% 3264
2020
Q3 		$664K Sell
44,985
-68,067
-60% -$1.28M ﹤0.01% 3212
2020
Q2 		$2.37M Sell
113,052
-27,673
-20% -$711K ﹤0.01% 2244
2020
Q1 		$3.25M Sell
140,725
-7,416
-5% -$186K ﹤0.01% 1791
2019
Q4 		$3.84M Buy
148,141
+60,976
+70% +$1.18M ﹤0.01% 2069
2019
Q3 		$1.7M Buy
87,165
+65,288
+298% +$1.32M ﹤0.01% 2603
2019
Q2 		$357K Sell
21,877
-21,402
-49% -$434K ﹤0.01% 3594
2019
Q1 		$981K Buy
43,279
+4,298
+11% +$109K ﹤0.01% 2907
2018
Q4 		$997K Buy
38,981
+5,398
+16% +$146K ﹤0.01% 2778
2018
Q3 		$1.1M Sell
33,583
-15,601
-32% -$425K ﹤0.01% 2796
2018
Q2 		$1.11M Sell
49,184
-5,665
-10% -$135K ﹤0.01% 2934
2018
Q1 		$1.33M Buy
54,849
+8,757
+19% +$241K ﹤0.01% 2760
2017
Q4 		$1.28M Sell
46,092
-13,119
-22% -$388K ﹤0.01% 2799
2017
Q3 		$2.03M Buy
59,211
+24,974
+73% +$817K ﹤0.01% 2535
2017
Q2 		$1.36M Sell
34,237
-5,009
-13% -$193K ﹤0.01% 2491
2017
Q1 		$1.45M Sell
39,246
-7,942
-17% -$254K ﹤0.01% 2594
2016
Q4 		$1.5M Sell
47,188
-69,442
-60% -$2.15M ﹤0.01% 2669
2016
Q3 		$4.23M Sell
116,630
-6,392
-5% -$178K ﹤0.01% 1797
2016
Q2 		$2.79M Buy
123,022
+19,043
+18% +$411K ﹤0.01% 2083
2016
Q1 		$1.96M Sell
103,979
-1,736
-2% -$28.4K ﹤0.01% 2229
2015
Q4 		$1.73M Buy
105,715
+4,012
+4% +$63.7K ﹤0.01% 2388
2015
Q3 		$1.12M Sell
101,703
-28,649
-22% -$365K ﹤0.01% 2721
2015
Q2 		$1.7M Buy
130,352
+14,349
+12% +$223K ﹤0.01% 2686
2015
Q1 		$2.01M Buy
116,003
+3,039
+3% +$55.7K ﹤0.01% 2391
2014
Q4 		$1.69M Buy
112,964
+19,812
+21% +$345K ﹤0.01% 2693
2014
Q3 		$2.15M Buy
93,152
+35,559
+62% +$1.03M ﹤0.01% 2432
2014
Q2 		$1.84M Buy
+57,593
New +$1.73M ﹤0.01% 2799

Other funds holding TBPH

WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Credit Suisse's TBPH Position: Q1 2024 in Review

Credit Suisse held its Theravance Biopharma (TBPH) position steady in Q1 2024 at 115,418 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2244.

Credit Suisse first reported a position in TBPH in Q2 2014 and has held it in 40 quarters since. The position peaked at $4.23M in Q3 2016. 121 funds tracked by Wall St. Rank hold TBPH as of Q1 2024.

  • Credit Suisse held 115,418 shares of Theravance Biopharma worth $1.04M as of Q1 2024.
  • Credit Suisse left its Theravance Biopharma share count unchanged in Q1 2024.
  • Theravance Biopharma made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2244 holding.
  • Credit Suisse first reported a position in Theravance Biopharma in Q2 2014 and has held it in 40 quarters since.
  • Credit Suisse's Theravance Biopharma position peaked at $4.23M in Q3 2016.
  • 121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.